Mereo BioPharma Granted Nasdaq Extension to Regain Compliance
TipRanks (Wed, 19-Aug 8:21 AM ET)
TipRanks (Mon, 17-Aug 7:40 AM ET)
Mereo BioPharma’s Alvelestat Deal and Improved Cash Runway Pave Path for 2027 Growth
Market Chameleon (Tue, 11-Aug 5:55 AM ET)
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Globe Newswire (Tue, 11-Aug 8:15 AM ET)
PRNewswire (Tue, 11-Aug 8:01 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
Mereo BioPharma Extends Cash Runway to Mid-2027 Amid Mixed Setrusumab Phase 3 Results
Market Chameleon (Mon, 12-Jan 5:31 AM ET)
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Mereo Biopharma Group PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol MREO.
As of August 19, 2026, MREO stock price was flat at $0.31 with 980,809 million shares trading.
MREO has a beta of 2.79, meaning it tends to be more sensitive to market movements. MREO has a correlation of 0.04 to the broad based SPY ETF.
MREO has a market cap of $49.72 million. This is considered a Sub-Micro Cap stock.
Last quarter Mereo Biopharma Group PLC - American Depositary Shares reported $0 in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-863,830 and met earnings estimates .
In the last 3 years, MREO traded as high as $5.02 and as low as $.20.
The top ETF exchange traded funds that MREO belongs to (by Net Assets): GWX.
MREO has underperformed the market in the last year with a price return of -81.5% while the SPY ETF gained +20.7%. However, in the short term, MREO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +31.2% vs +4.4% return in SPY. But in the last 2 weeks, MREO shares have been beat by the market, returning -3.3% compared to an SPY return of -0.3%.
MREO support price is $.30 and resistance is $.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MREO shares will trade within this expected range on the day.